Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for genedrive in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 5.38.
Current Consensus is
N/A
The current consensus among 0 polled investment analysts is to n/a stock in genedrive. This N/A consensus rating has held steady for over two years.
genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive system, a rapid thermocycler and signal detection system and semi- automated system used forqualitative in vitro molecular diagnostic tests; and Genedrive CYP2C19 ID Kit, a point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings. It also offers Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of HCV infection prior to drug administration, pathogen detection of biological military threats and a point-of-care for COVID-19 detection system for use in areas, such as healthcare, workplace screening, travel requirements, and confirmation of antigen tests. It serves medical, biotechnology, and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.
Read More
